{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:50:43Z","timestamp":1772005843002,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Antiphospholipid antibodies (aPL) are described in individuals with leprosy without the clinical features of antiphospholipid antibody syndrome (APS), a condition involving thromboembolic phenomena. We have described the persistence of these antibodies for over 5 years in patients with leprosy after specific treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>To determine whether epidemiological, clinical and immunological factors played a role in the long-term persistence of aPL antibodies in leprosy patients after multidrug therapy (MDT) had finished.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The study sample consisted of 38 patients with a diagnosis of leprosy being followed up at the Dermatology and Venereology Outpatient Department at the Alfredo da Matta Foundation (FUAM) in Manaus, AM. ELISA was used to detect anticardiolipin (aCL) and anti-\u03b2<jats:sub>2<\/jats:sub> glycoprotein I (anti<jats:bold>-<\/jats:bold>\u03b2<jats:sub>2<\/jats:sub>GPI) antibodies. Patients were reassessed on average of 5 years after specific treatment for the disease (MDT) had been completed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Persistence of aPL antibodies among the 38 leprosy patients was 84% (32\/38), and all had the IgM isotype. Mean age was 48.1\u2009\u00b1\u200915.9\u2009years, and 23 (72.0%) were male. The lepromatous form (LL) of leprosy was the most common (<jats:italic>n<\/jats:italic>\u2009=\u200916, 50%). Reactional episodes were observed in three patients (9.4%). Eighteen (47.37%) were still taking medication (prednisone and\/or thalidomide). Mean IgM levels were 64\u2009U\/mL for aCL and 62\u2009U\/mL for anti-\u03b2<jats:sub>2<\/jats:sub>GPI. In the multivariate binary logistic regression the following variables showed a significant association: age (<jats:italic>p<\/jats:italic>\u2009=\u20090.045, OR\u2009=\u20090.91 and CI 95% 0.82\u20130.98), LL clinical presention (<jats:italic>p<\/jats:italic>\u2009=\u20090.034; OR\u2009=\u20090.02 and CI 95%\u2009=\u20090.0\u20130.76) and bacterial index (<jats:italic>p<\/jats:italic>\u2009=\u20090.044; OR\u2009=\u20092.74 and CI 95%\u2009=\u20091.03\u20137.33). We did not find association between prednisone or thalidomide doses and positivity for aPL (<jats:italic>p<\/jats:italic>\u2009=\u20090.504 and <jats:italic>p<\/jats:italic>\u2009=\u20090.670, respectively). No differences in the variables vascular thrombosis, pregnancy morbidity, diabetes, smoking and alcoholism were found between aPL-positive and aPL-negative patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Persistence of positivity for aPL antibodies was influenced by age, clinical presentation and bacterial index. However, further studies are needed to elucidate the reason for this persistence, the role played by aPL antibodies in the disease and the B cell lineages responsible for generation of these antibodies.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s42358-019-0094-4","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T18:03:12Z","timestamp":1574964192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Epidemiological, clinical and immune factors that influence the persistence of antiphospholipid antibodies in leprosy"],"prefix":"10.1186","volume":"59","author":[{"given":"Sandra L\u00facia Euz\u00e9bio","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena L\u00facia Alves","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5597-7343","authenticated-orcid":false,"given":"Antonio Luiz","family":"Boechat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neusa Pereira","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia Ionue","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"das Gra\u00e7as Souza Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Fernando","family":"de Souza Passos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Dos-Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"issue":"8","key":"94_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1191\/096120300678828712","volume":"9","author":"GF de Larra\u00f1aga","year":"2000","unstructured":"de Larra\u00f1aga GF, Forastiero RR, Martinuzzo ME, et al. High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity. Lupus. 2000;9(8):594\u2013600.","journal-title":"Lupus."},{"issue":"1","key":"94_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/art.1780400115","volume":"40","author":"S Loizou","year":"1997","unstructured":"Loizou S, Cazabon JK, Walport MJ, Tait D, So AK. Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum. 1997;40(1):103\u20138.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"94_CR3","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1002\/art.11038","volume":"48","author":"P Landenberg Von","year":"2003","unstructured":"Landenberg Von P, Lehmann HW, Kn\u00f6ll A, Dorsch S, Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum. 2003;48(7):1939\u201347.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"94_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.5045\/kjh.2011.46.1.36","volume":"46","author":"JY Huh","year":"2011","unstructured":"Huh JY, Yi DY, Hwang SG, Choi JJ, Kang MS. Characterization of antiphospholipid antibodies in chronic hepatitis B infection. Korean J Hematol. 2011;46(1):36\u201340.","journal-title":"Korean J Hematol"},{"issue":"1","key":"94_CR5","first-page":"30","volume":"36","author":"SL Ribeiro","year":"2011","unstructured":"Ribeiro SL, Pereira HL, Silva NP, Souza AW, Sato EI. Anti-\u03b22-glycoprotein I antibodies are highly prevalent in a large number of Brazilian leprosy patients. Acta Reumatol Port. 2011;36(1):30\u20137.","journal-title":"Acta Reumatol Port"},{"issue":"4","key":"94_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jcv.2012.12.011","volume":"56","author":"E Ben-Chetrit","year":"2013","unstructured":"Ben-Chetrit E, Wiener-Well Y, Fadeela A, Wolf DG. Antiphospholipid antibodies during infectious mononucleosis and their long term clinical significance. J Clin Virol. 2013;56(4):312\u20135.","journal-title":"J Clin Virol"},{"issue":"12","key":"94_CR7","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1177\/0961203314529469","volume":"23","author":"SLE Ribeiro","year":"2014","unstructured":"Ribeiro SLE, Pereira HLA, Silva NP, Sato EI, Passos LFS, dos MC S. Long-term persistence of anti-\u03b22 glycoprotein I in treated leprosy patients. Lupus. 2014;23(12):1249\u201351.","journal-title":"Lupus."},{"issue":"1","key":"94_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1078\/0171-2985-00213","volume":"207","author":"R Cervera","year":"2003","unstructured":"Cervera R, Asherson RA. Clinical and epidemiological aspects in the antiphospholipid syndrome. Immunobiology. 2003;207(1):5\u201311.","journal-title":"Immunobiology."},{"issue":"9","key":"94_CR9","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/art.1780390903","volume":"39","author":"RA Roubey","year":"1996","unstructured":"Roubey RA. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum. 1996;39(9):1444\u201354.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"94_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1006\/jaut.2000.0401","volume":"15","author":"LO Carreras","year":"2000","unstructured":"Carreras LO, Forastiero RR, Martinuzzo ME. Which are the best biological markers of the antiphospholipid syndrome? J Autoimmun. 2000;15(2):163\u201372.","journal-title":"J Autoimmun"},{"issue":"4","key":"94_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1055\/s-0037-1613055","volume":"87","author":"J Arvieux","year":"2002","unstructured":"Arvieux J, Renaudineau Y, Mane I, Perraut R, Krilis SA, Youinou P. Distinguishing features of anti-beta2 glycoprotein I antibodies between patients with leprosy and the antiphospholipid syndrome. Thromb Haemost. 2002;87(4):599\u2013605.","journal-title":"Thromb Haemost"},{"issue":"2","key":"94_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1191\/0961203305lu2048oa","volume":"14","author":"RR Forastiero","year":"2005","unstructured":"Forastiero RR, Martinuzzo ME, de Larra\u00f1aga GF. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus. 2005;14(2):129\u201336.","journal-title":"Lupus."},{"issue":"4","key":"94_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/BF00407745","volume":"278","author":"F Furukawa","year":"1986","unstructured":"Furukawa F, Kashihara M, Imamura S, Ohshio G, Hamashima Y. Evaluation of anti-cardiolipin antibody and its cross-reactivity in sera of patients with lepromatous leprosy. Arch Dermatol Res. 1986;278(4):317\u20139.","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"94_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/BF02031064","volume":"8","author":"MB Santiago","year":"1989","unstructured":"Santiago MB, Cossermelli W, Tuma MF, Pinto MN, Oliveira RM. Anticardiolipin antibodies in patients with infectious diseases. Clin Rheumatol. 1989;8(1):23\u20138.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"94_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1177\/096120339400300615","volume":"3","author":"M Hojnik","year":"1994","unstructured":"Hojnik M, Gilburd B, Ziporen L, et al. Anticardiolipin antibodies in infections are heterogenous in their dependency on beta 2-glycoprotein I: analysis of anticardiolipin antibodies in leprosy. Lupus. 1994;3(6):515\u201321.","journal-title":"Lupus."},{"issue":"3","key":"94_CR16","first-page":"307","volume":"66","author":"G Thawani","year":"1994","unstructured":"Thawani G, Bhatia VN, Mukherjee A. Anticardiolipin antibodies in leprosy. Indian J Lepr. 1994;66(3):307\u201314.","journal-title":"Indian J Lepr"},{"issue":"3","key":"94_CR17","first-page":"387","volume":"66","author":"P Fiallo","year":"1998","unstructured":"Fiallo P, Nunzi E, Cardo PP. beta2-glycoprotein I-dependent anticardiolipin antibodies as risk factor for reactions in borderline leprosy patients. Int J Lepr Other Mycobact Dis. 1998;66(3):387\u20138.","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"4","key":"94_CR18","first-page":"376","volume":"69","author":"P Fiallo","year":"1998","unstructured":"Fiallo P, Travaglino C, Nunzi E, Cardo PP. Beta 2-glycoprotein I-dependence of anticardiolipin antibodies in multibacillary leprosy patients. Lepr Rev. 1998;69(4):376\u201381.","journal-title":"Lepr Rev"},{"issue":"4","key":"94_CR19","first-page":"492","volume":"18","author":"A Elbeialy","year":"2000","unstructured":"Elbeialy A, Strassburger-Lorna K, Atsumi T, et al. Antiphospholipid antibodies in leprotic patients: a correlation with disease manifestations. Clin Exp Rheumatol. 2000;18(4):492\u20134.","journal-title":"Clin Exp Rheumatol"},{"key":"94_CR20","unstructured":"Repka JCD, Skare TL, Salles Jr G, Paul GM. Anticardiolipin antibodies in leprosy patients. Braz J Rheumatol. 2001;41(1):1\u20136."},{"issue":"3","key":"94_CR21","first-page":"203","volume":"68","author":"A Le Grand","year":"1997","unstructured":"Le Grand A. Women and leprosy: a review. Lepr Rev. 1997;68(3):203\u201311.","journal-title":"Lepr Rev"},{"key":"94_CR22","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/B978-0-12-384864-2.00017-2","volume-title":"Statistics in Medicine","author":"R.H. Riffenburgh","year":"2012","unstructured":"Riffenburgh RH. Statistics in medicine. 30th ed. London: Elsevier; 2012."},{"issue":"4","key":"94_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00281-004-0188-9","volume":"26","author":"ECB Milner","year":"2005","unstructured":"Milner ECB, Anolik J, Cappione A, Sanz I. Human innate B cells: a link between host defense and autoimmunity? Springer Semin Immunopathol. 2005;26(4):433\u201352.","journal-title":"Springer Semin Immunopathol"},{"issue":"4","key":"94_CR24","doi-asserted-by":"crossref","first-page":"344","DOI":"10.47276\/lr.82.4.344","volume":"82","author":"JS Spencer","year":"2011","unstructured":"Spencer JS, Brennan PJ. The role of mycobacterium leprae phenolic glycolipid I (PGL-I) in serodiagnosis and in the pathogenesis of leprosy. Lepr Rev. 2011;82(4):344\u201357.","journal-title":"Lepr Rev"},{"issue":"3","key":"94_CR25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.imbio.2011.07.008","volume":"217","author":"A Gupta","year":"2012","unstructured":"Gupta A, Kaul A, Tsolaki AG, Kishore U, Bhakta S. Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology. 2012;217(3):363\u201374.","journal-title":"Immunobiology."},{"issue":"4\u20135","key":"94_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s150100050033","volume":"27","author":"S Albert","year":"1999","unstructured":"Albert S, Schulze J, Riegel H, Brade V. Lyme arthritis in a 12-year-old patient after a latency period of 5 years. Infection. 1999;27(4\u20135):286\u20138.","journal-title":"Infection."},{"issue":"1","key":"94_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1600-065X.2011.01074.x","volume":"245","author":"DW White","year":"2012","unstructured":"White DW, Suzanne Beard R, Barton ES. Immune modulation during latent herpesvirus infection. Immunol Rev. 2012;245(1):189\u2013208.","journal-title":"Immunol Rev"},{"key":"94_CR28","doi-asserted-by":"crossref","unstructured":"Duarte-Garcia A, Pham M, Crowson CS et al. The epidemiology of antiphospholipid syndrome: a population based study. Arthritis Rheum. 2019;71(9):1545\u201352.","DOI":"10.1002\/art.40901"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-019-0094-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s42358-019-0094-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-019-0094-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:47:16Z","timestamp":1606438036000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-019-0094-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["94"],"URL":"https:\/\/doi.org\/10.1186\/s42358-019-0094-4","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"4 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients signed an Informed Consent Form, and the study was approved by the Ethics Committee of the Funda\u00e7\u00e3o Alfredo da Matta No. 008\u201310.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}